Multinational randomized phase III trial with or without consolidation chemotherapy using docetaxel and cisplatin after concurrent chemoradiation in inoperable stage III non-small-cell lung cancer: KCSG-LU05-04

Journal of Clinical Oncology

Volumn 33, Issue 24, 2015, Pages 2660-2666

  Ahn, Jin Seok ^a   Ahn, Yong Chan ^a   Kim, Joo Hang ^b   Lee, Chang Geol ^b   Cho, Eun Kyung ^h   Lee, Kyu Chan ^h   Chen, Ming ⁿ   Kim, Dong Wan ^c   Kim, Hoon Kyo ⁱ   Min, Young Joo ^k   Kang, Jin Hyoung ^d   Choi, Jin Hyuck ^j   Kim, Sang We ^f   Zhu, Guangying ^o   Wu, Yi Long ^p   Kim, Sung Rok ^e   Lee, Kyung Hee ^l   Song, Hong Suk ^m   Choi, Yoon La ^a   Sun, Jong Mu ^a   Jung, Sin Ho ^g   Ahn, Myung Ju ^a   Park, Keunchil ^a   more..

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Seoul National University Hospital   (South Korea)

^d The Catholic University of Korea   (South Korea)

^e Inje University   (South Korea)

^f University of Ulsan College of Medicine   (South Korea)

^g Samsung Medical Center   (South Korea)

^h Gachon University   (South Korea)

ⁱ The Catholic University of Korea   (South Korea)

^j Ajou University Medical CentSuwon   (South Korea)

^k University of Ulsan College of Medicine   (South Korea)

^l Yeungnam University Hospital   (South Korea)

^m Dongsan Medical Center   (South Korea)

ⁿ SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^o PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^p GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOCETAXEL; ANTINEOPLASTIC AGENT; TAXOID;

ADULT; ADVANCED CANCER; AGED; ALLERGIC REACTION; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CHEMORADIOTHERAPY; CLINICAL OBSERVATION; CONSOLIDATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG WITHDRAWAL; ESOPHAGITIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NON SMALL CELL LUNG CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE FRACTIONATION; RADIATION PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT INDICATION; VOMITING; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; LUNG NEOPLASMS; PATHOLOGY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; CISPLATIN; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; TAXOIDS;

EID: 84940484434     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.60.0130     Document Type: Article

References (44)

1. Jemal A, Bray F, Center MM, et al: Global cancer statistics. CA Cancer J Clin 61:69-90, 2011
2. Jung KW, Won YJ, Kong HJ, et al: Cancer statistics in Korea: Incidence, mortality, survival and prevalence in 2010. Cancer Res Treat 45:1-14, 2013
3. Goldstraw P, Crowley J, Chansky K, et al: The IASLC Lung Cancer Staging Project: Proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2:706-714, 2007
4. Schrum D, Carter D, Kelsey C, et al: Non-Small Cell Lung Cancer (ed 9). Philadelphia, PA, Lippincott Williams & Wilkins, 2011, pp 799-847
5. Dillman RO, Seagren SL, Propert KJ, et al: A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med 323:940-945, 1990
6. Sause W, Kolesar P, Taylor S IV, et al: Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 117:358-364, 2000
7. Le Chevalier T, Arriagada R, Quoix E, et al: Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: First analysis of a randomized trial in 353 patients. J Natl Cancer Inst 83:417-423, 1991
8. Schaake-Koning C, van den Bogaert W, Dalesio O, et al: Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 326:524-530, 1992
9. Jeremic B, Shibamoto Y, Acimovic L, et al: Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: A randomized study. J Clin Oncol 14:1065-1070, 1996
10. Jeremic B, Shibamoto Y, Acimovic L, et al: Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer. J Clin Oncol 13:452-458, 1995
11. Curran WJ Jr, Paulus R, Langer CJ, et al: Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: Randomized phase III trial RTOG 9410. J Natl Cancer Inst 103:1452-1460, 2011
12. Furuse K, Fukuoka M, Kawahara M, et al: Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17:2692-2699, 1999
13. Aupérin A, Le Péchoux C, Pignon JP, et al: Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): A meta-analysis of individual data from 1764 patients. Ann Oncol 17:473-483, 2006
14. Gandara DR, Chansky K, Albain KS, et al: Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: Phase II Southwest Oncology Group Study S9504. J Clin Oncol 21:2004-2010, 2003
15. Park J, Ahn YC, Kim H, et al: A phase II trial of concurrent chemoradiation therapy followed by consolidation chemotherapy with oral etoposide and cisplatin for locally advanced inoperable non-small cell lung cancers. Lung Cancer 42:227-235, 2003
16. Wu HG, Bang YJ, Choi EK, et al: Phase I study of weekly docetaxel and cisplatin concurrent with thoracic radiotherapy in stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 52:75-80, 2002
17. Park K, Ahn Y, Kim J, et al: A multinational phase III randomized trial with or without consolidation chemotherapy using docetaxel and cisplatin after concurrent chemoradiation in inoperable stage III non-small cell lung cancer (CCheIN): Interim analysis. J Clin Oncol 27, 2009 (suppl 15s; abstr 7538)
18. Fakhrejahani F, Hashemi Sadraei N, Mekhail T: The role of consolidation treatment in locally advanced unresectable NSCLC. Curr Oncol Rep 15:424-432, 2013
19. Tsujino K, Kurata T, Yamamoto S, et al: Is consolidation chemotherapy after concurrent chemo-radiotherapy beneficial for patients with locally advanced non-small-cell lung cancer? A pooled analysis of the literature. J Thorac Oncol 8:1181-1189, 2013
20. Katayama H, Ueoka H, Kiura K, et al: Preoperative concurrent chemoradiotherapy with cisplatin and docetaxel in patients with locally advanced non-small-cell lung cancer. Br J Cancer 90:979-984, 2004
21. Mudad R, Ramsey M, Kovitz K, et al: Concomitant weekly docetaxel, cisplatin and radiation therapy in locally advanced non-small cell lung cancer: A dose finding study. Lung Cancer 39:173-177, 2003
22. Kiura K, Ueoka H, Segawa Y, et al: Phase I/II study of docetaxel and cisplatin with concurrent thoracic radiation therapy for locally advanced non-small-cell lung cancer. Br J Cancer 89:795-802, 2003
23. Segawa Y, Kiura K, Takigawa N, et al: Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007. J Clin Oncol 28:3299-3306, 2010
24. Bria E, Cuppone F, Ciccarese M, et al: Weekly docetaxel as second line chemotherapy for advanced non-small-cell lung cancer: Meta-analysis of randomized trials. Cancer Treat Rev 32:583-587, 2006
25. Camps C, Massuti B, Jiménez A, et al: Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: A Spanish Lung Cancer Group trial. Ann Oncol 17:467-472, 2006
26. Gridelli C, Gallo C, Di Maio M, et al: A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study. Br J Cancer 91:1996-2004, 2004
27. Schuette W, Nagel S, Blankenburg T, et al: Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel. J Clin Oncol 23:8389-8395, 2005
28. Davidoff AJ, Gardner JF, Seal B, et al: Population-based estimates of survival benefit associated with combined modality therapy in elderly patients with locally advanced non-small cell lung cancer. J Thorac Oncol 6:934-941, 2011
29. Socinski MA, Zhang C, Herndon JE 2nd, et al: Combined modality trials of the Cancer and Leukemia Group B in stage III non-small-cell lung cancer: Analysis of factors influencing survival and toxicity. Ann Oncol 15:1033-1041, 2004
30. Azuma K, Komohara Y, Sasada T, et al: Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy. Cancer Sci 98:1336-1343, 2007
31. Lord RV, Brabender J, Gandara D, et al: Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 8:2286-2291, 2002
32. Tiseo M, Bordi P, Bortesi B, et al: ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin. Br J Cancer 108:1695-1703, 2013
33. Azuma K, Sasada T, Kawahara A, et al: Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with a combination of cisplatin/docetaxel and concurrent thoracic irradiation. Cancer Chemother Pharmacol 64:565-573, 2009
34. Olaussen KA, Dunant A, Fouret P, et al: DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355:983-991, 2006
35. Friboulet L, Olaussen KA, Pignon JP, et al: ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N Engl J Med 368:1101-1110, 2013
36. Bepler G, Williams C, Schell MJ, et al: Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 31:2404-2412, 2013
37. Seve P, Mackey J, Isaac S, et al: Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Mol Cancer Ther 4:2001-2007, 2005
38. Seve P, Isaac S, Tredan O, et al: Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy. Clin Cancer Res 11:5481-5486, 2005
39. Dumontet C, Isaac S, Souquet PJ, et al: Expression of class III beta tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy. Bull Cancer 92:E25-E30, 2005
40. Seve P, Lai R, Ding K, et al: Class III beta-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: Analysis of NCIC JBR.10. Clin Cancer Res 13:994-999, 2007
41. Kerr KM, Bubendorf L, Edelman MJ, et al: Second ESMO consensus conference on lung cancer: Pathology and molecular biomarkers for non-small-cell lung cancer. Ann Oncol 25:1681-1690, 2014
42. Vokes E, Wang L, Vansteenkiste J, et al: Preliminary safety and treatment delivery data during concurrent phase of chemoradiation therapy of the PROCLAIM trial: A phase 3 trial of pemetrexed, cisplatin, and radiotherapy followed by consolidation pemetrexed versus etoposide, cisplatin, and radiotherapy followed by consolidation cytotoxic chemotherapy of choice in patients with stage III nonsquamous cell lung cancer. J Thorac Oncol 8:S551-S552, 2013 (suppl)
43. Bradley JD, Paulus R, Komaki R, et al: A randomized phase III comparison of standard-dose (60 Gy) versus high-dose (74 Gy) conformal chemoradiotherapy with or without cetuximab for stage III non-small cell lung cancer: Results on radiation dose in RTOG 0617. J Clin Oncol 31, 2013 (suppl; abstr 7501)
44. Butts C, Socinski MA, Mitchell PL, et al: Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): A randomised, double-blind, phase 3 trial. Lancet Oncol 15:59-68, 2014